Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol plus methotrexate in DMARD-naive adults with early active rheumatoid arthritis
2011-001729-25Phase 3Completed
- Sponsor
- UCB
- Start
- Jan 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Certolizumab pegol + methotrexate with Placebo + methotrexate (2 arms). Primary endpoint: Sustained low disease activity at Week 52. Started Jan 2012; status: completed.
02
Drugs
certolizumab pegolmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-001729-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001729-25.